M&A Activity in the Biotech Industry at a Four-Year High as Large Pharmaceuticals Look to Replace Lose Revenues

Five Star Equities Provides Stock Research on AEterna Zentaris and Cytokinetics

Marketwired

NEW YORK, NY--(Marketwire -08/17/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation, such as the FAST and TREAT acts, have helped boost investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund is up over 28 percent in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on AEterna Zentaris Inc. (AEZS) and Cytokinetics, Inc. (CYTK).

Access to the full company reports can be found at:

www.FiveStarEquities.com/AEZS

www.FiveStarEquities.com/CYTK

The FAST and TREAT acts introduced in 2012 have helped accelerate the development, review and approval process of medicines/personalized therapies for patients suffering from serious and life-threatening diseases. According to recent data from Thomas Reuters, biotech mergers & acquisitions activity is currently at a four-year high as large pharmaceuticals are facing major patent cliffs. So far in 2012 the volume of biotech M&A has exceeded $25 billion, compared to roughly 10 billion in the same period of 2011.

"Their patents have expired, and as a result they have holes in their revenue line they are trying to fill," said Scott Lindsay, global head of mergers and acquisitions at Credit Suisse. "The other part is just shoring up the pipeline they have. So even if they don't have a major patent problem, they're all looking for growth."

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

AEterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For the second quarter 2012 the company reported a net income of $4.5 million, compared to a net loss of 10.6 million in the year prior quarter.

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbill, is in Phase II clinical development for the potential treatment of heart failure.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer

Contact:

Five Star Equities
Email Contact

Rates

View Comments (0)